Resumen de acción LLY
Eli Lilly and Company descubre, desarrolla y comercializa productos farmacéuticos para uso humano en todo el mundo.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Narratives
BetaNarratives bring a range of perspectives from our community.
Competidores de Eli Lilly and Company
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$733.51 |
| 52 Week High | US$800.78 |
| 52 Week Low | US$392.26 |
| Beta | 0.37 |
| 1 Month Change | -5.71% |
| 3 Month Change | 13.73% |
| 1 Year Change | 80.75% |
| 3 Year Change | 294.53% |
| 5 Year Change | 528.81% |
| Change since IPO | 26,016.63% |
Noticias y actualizaciones recientes
What You Can Learn From Eli Lilly and Company's (NYSE:LLY) P/S
Apr 22
Wall Street Lunch: Lilly In Limelight
Apr 17Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets
Mar 29Recent updates
What You Can Learn From Eli Lilly and Company's (NYSE:LLY) P/S
Apr 22Wall Street Lunch: Lilly In Limelight
Apr 17Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets
Mar 29Eli Lilly: The Party Is Not Over
Mar 23Estimating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)
Mar 17Eli Lilly: Yes, It Is Too Late To Join The Party
Feb 20Eli Lilly: Overvaluation Is A Big Red Flag
Feb 14Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade)
Feb 07Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value
Jan 31Eli Lilly (NYSE:LLY) Has Announced That It Will Be Increasing Its Dividend To $1.30
Jan 24Eli Lilly: The Cupboard Is Fully Stocked
Jan 19Eli Lilly: The Buzz Is Not Over
Jan 11Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.30
Jan 10Eli Lilly (NYSE:LLY) Is Paying Out A Larger Dividend Than Last Year
Dec 27Pinning Down Eli Lilly and Company's (NYSE:LLY) P/S Is Difficult Right Now
Dec 24Eli Lilly: Long Path To A Trillion
Dec 21Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet
Dec 05Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly
Nov 30Eli Lilly: Perfectly Priced Healthcare Giant
Nov 16Eli Lilly: Zepbound For Weight Loss FDA Approved - Time To Believe The Hype?
Nov 09Calculating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)
Oct 30Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated
Oct 11Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase
Oct 05Eli Lilly: Don't Be Fooled By Greed
Sep 20Eli Lilly Stock Hits New All-Time Highs: Is It Still A Buy?
Sep 11Here's Why We Think Eli Lilly (NYSE:LLY) Is Well Worth Watching
Sep 11Is Eli Lilly (NYSE:LLY) Using Too Much Debt?
Aug 24Sell Eli Lilly And Buy This Coiled-Spring Dividend Aristocrat Instead
Aug 23Eli Lilly Q2: Dividends Don't Lie
Aug 14Eli Lilly Remains A Buy With Strong Sales And Possible Upside With Mounjaro
Aug 08Rentabilidad de los accionistas
| LLY | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 0.3% | -0.01% | 2.0% |
| 1Y | 80.8% | 9.5% | 22.3% |
Rentabilidad vs. Industria: LLY superó al sector US Pharmaceuticals , que obtuvo un rendimiento del 9.5% el año pasado.
Rentabilidad vs. Mercado: LLY superó al mercado US, que obtuvo un rendimiento del 24.9% el año pasado.
Volatilidad de los precios
| LLY volatility | |
|---|---|
| LLY Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: LLY no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de LLY (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company descubre, desarrolla y comercializa productos farmacéuticos de uso humano en todo el mundo. La empresa ofrece Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulina lispro, insulina lispro protamina, insulina lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R y Humulin U-500 para la diabetes; Jardiance, Mounjaro y Trulicity para la diabetes de tipo 2; y Zepbound para la obesidad. También ofrece productos oncológicos, como Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt y Verzenio.
Resumen de fundamentos de Eli Lilly and Company
| Estadísticas fundamentales de LLY | |
|---|---|
| Capitalización bursátil | US$660.72b |
| Beneficios(TTM) | US$5.24b |
| Ingresos (TTM) | US$34.12b |
126.1x
Ratio precio-beneficio (PE)19.4x
Ratio precio-ventas (PS)¿Está LLY sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de LLY | |
|---|---|
| Ingresos | US$34.12b |
| Coste de los ingresos | US$7.08b |
| Beneficio bruto | US$27.04b |
| Otros gastos | US$21.80b |
| Beneficios | US$5.24b |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
Apr 30, 2024
| Beneficios por acción (BPA) | 5.82 |
| Margen bruto | 79.25% |
| Margen de beneficio neto | 15.36% |
| Ratio deuda/patrimonio | 233.4% |
¿Cómo se ha desempeñado LLY a largo plazo?
Ver rendimiento histórico y comparativa